Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01839916 · OUTCOME

Treatment-related Mortality

Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies · Source last updated 2019-08-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of patients
Interval / dispersion
95% Confidence Interval
Time frame
At 2 year

What was measured

Estimated by cumulative incidence method. Cumulative incidence of treatment-related mortality with relapse of the original disease as the competing risk will be calculated.

Analysis population: Patients received at least one DLI treatment.

Groups in this outcome

Treatment (DLI)

Patients receive DLI IV. Treatment repeats every 4-8 weeks for 5 doses in the absence of disease progression or unacceptable toxicity. therapeutic allogeneic lymphocytes: Given IV laboratory biomarker analysis: Correlative studies

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (DLI)36

Reported measurements

Source class 1
Values in percentage of patients · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Treatment (DLI)12.1Not reported3.725.9Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        3.7
        upper Limit
        25.9
        value
        12.1
denoms
  1. counts
    1. group Id
      OG000
      value
      36
    units
    Participants
description
Estimated by cumulative incidence method. Cumulative incidence of treatment-related mortality with relapse of the original disease as the competing risk will be calculated.
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients receive DLI IV. Treatment repeats every 4-8 weeks for 5 doses in the absence of disease progression or unacceptable toxicity. therapeutic allogeneic lymphocytes: Given IV laboratory biomarker analysis: Correlative studies
    id
    OG000
    title
    Treatment (DLI)
param Type
NUMBER
population Description
Patients received at least one DLI treatment.
reporting Status
POSTED
time Frame
At 2 year
title
Treatment-related Mortality
type
SECONDARY
unit Of Measure
percentage of patients

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice